Navigation Links
Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
Date:4/9/2008

break repair pathways including homologous recombination

Session: Stress Responses

Abstract #1859

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

-- Ex vivo activity of SNS-595 against biopsies of acute myeloid leukemia,

triple negative breast and ovarian cancers supports ongoing and

potential clinical indications

Session: Novel Drug Targets, Agents and Mechanisms

Abstract #2830

1:00 p.m. - 5:00 p.m. Exhibit Hall B-F, San Diego Convention Center

Suzanne Trudel, MSc, M.D., Assistant Professor, Princess Margaret Hospital, University Health Network, will provide an oral presentation on SNS-032's preclinical activity in multiple myeloma as part of a minisymposium on Tuesday, April 15, 2008. In addition, translational research data detailing the relationship between SNS-032's mechanism and its activity in certain types of cancer will be presented in a poster. SNS-032, a potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory chronic lymphocytic leukemia or multiple myeloma.

SNS-032 Oral Presentation

Tuesday, April 15, 2008

-- SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates

preclinical activity in human multiple myeloma

Minisymposium: Novel Genomic Approaches, Drugs, Targets, and Strategies

Abstract #4972

4:55 p.m. to 5:10 p.m. Room 30A-C, San Diego Convention Center

SNS-032 Poster Presentation

Sunday, April 13, 2008

-- SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7, and 9,

blocks transcription of cyclin D1 and Mcl-1, causing cell death in

mantle cell lymphoma cell lines

Session: Histone Deacetylase Inhibitors and Cell Cycle Inhibitors

Abstract #756

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convent
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
2. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
9. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research ... announced the addition of the "Medical Device ... to their offering. This report analyzes ... US$ Million by the following Device Categories: Class ... areas also analyzed in the report Include - ...
(Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
(Date:4/17/2015)... 2015 Steven Rash , the CEO of ... operating subsidiary American Seed & Oil Company, presented the ... yesterday in New York City.  Mr. Rash,s presentation featured ... Seed & Oil Company has recently announced the ... Seed Foods , the EpiVape , and ...
Breaking Medicine Technology:Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3
... Silence Therapeutics plc (AIM: SLN) ("Silence" or ... patent 7,893,245, titled "Interfering RNA Molecules," by the ... issued patent, which represents a continuation of previously ... RNAi molecules with defined positional modifications including siRNA ...
... Feb. 22, 2011 Covance Inc. (NYSE: CVD ... Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 2Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 3Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 4Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2
(Date:4/17/2015)... Wholelifelifeinsurance.org has released a new blog post ... policies . , Whole life insurance can help ... families at the same time. Whole life insurance is ... customized to it the client’s needs. , Whole ... some appropriate steps.Comparing life insurance quotes is very important ...
(Date:4/17/2015)... Verndale, a Global Experience Technology Company, is ... chosen as a Boston Business Journal (BBJ) Pacesetter, ranking ... region. The BBJ’s Pacesetters represents privately held businesses that ... This is the eighth consecutive year and the ninth ... been honored with this award. , “Being honored with ...
(Date:4/17/2015)... 17, 2015 Cheapquotesautoinsurance.com has released a new ... has a salvage title . , An auto insurance ... a salvage title if the owner has paid for all ... title car is not possible, while in other states, the ... blog post provides more information on the subject. , ...
(Date:4/17/2015)... 17, 2015 Founder of the ... as a keynote speaker at the Couples Conference from ... Marriott in Manhattan Beach, CA. Tatkin’s presentation and panel ... can help couples become “secure-functioning” – a term he ... of research in neurobiology, arousal regulation, and infant attachment ...
(Date:4/17/2015)... York (PRWEB) April 17, 2015 The ... announced that Long Island eye surgeon Jeffrey L. Martin, ... Laser Cataract Surgery Skills Transfer Session being held April ... Dr. Martin is the Managing Partner of North Shore ... assist fellow ophthalmologists attending the Skills Transfer Session in ...
Breaking Medicine News(10 mins):Health News:Whole Life Insurance Policies At Affordable Prices By Comparing Quotes 2Health News:Verndale Honored as 2015 Boston Business Journal Pacesetter, Named 46th Fastest Growing Private Company 2Health News:Compare Auto Insurance Quotes for Cars With A Salvage Title! 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 3Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 2Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 3
... ... ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. ... the 2009 American Society of Hematology ("ASH") Annual Meeting updated results ... pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive ...
... of Chicago have discovered a technique that is able to ... habitual snoring by screening their urine. "These findings ... test that could detect OSA in snoring children. This would ... children who snore, only about 20 to 30 percent of ...
... , OAK BROOK, Ill., Dec. 7 ... center (AMC) members for their achievements in UHC,s Supply ... are noted for modeling best practices in supply chain ... , The winners were determined using 2008 data and ...
... , , Consumers ... SILVER SPRING, Md., Dec. 6 The U.S. Food and Drug ... San Antonio Bay on or after Nov. 16 due to reports ... from this area, which is located on the Gulf of Texas. ...
... have discovered that the loss of a key segment of DNA ... to show that this kind of genetic alteration can cause obesity. ... study, led by Dr Sadaf Farooqi from the University of Cambridge ... at 300 children with severe obesity. The team scanned each ...
... find signs of feline DNA in virus , SUNDAY, Dec. 6 ... might be found in a tiger that lived thousands or millions ... virus took on a bit of a tiger,s genetic material, scientists ... to this day. That tiger, in fact, may have bitten a ...
Cached Medicine News:Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Urine test for pediatric obstructive sleep apnea possible 2Health News:Recognized Top Performers in UHC Supply Chain 2Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:AIDS May Date Back to Ancient Tiger 2
The Salt A-Peel™ microdermabrasion combines, positive air pressure, pure salt, ultrasound and the application of rich anti oxidant products to deliver a remarkable 'The Salt A-Peel' anti ageing...
... introduces the DiamondTome™ Skin Resurfacing System ... DiamondTome™ Wands, an evolution in microdermabrasion ... smoother, more youthful skin. , For ... benefits of DiamondTome's™ innovative approach to ...
... your aesthetic practice with the advantages of ... that's gentle, powerful and fast. With ever-increasing ... of IPL Skin Treatments using Photorejuvenation, the ... an indispensable tool for all aesthetic physicians, ...
Disposable. Sterile Suction Tubing....
Medicine Products: